Search
Botanix executive director Matthew Callahan.

Botanix makes ASX debut

Medical dermatology company Botanix Pharmaceuticals has enjoyed healthy gains on its first day of trading on the ASX, after completing a reverse takeover of Bone Medical.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Top 10 Shareholders

Substantial shareholders as published in the annual report.
Source: Morningstar

Total Shareholder Return as at 31/10/19

1 year TSR5 year TSR
47thPharmAust145%-9%
174thBotanix Pharmaceuticals39%27%
608thNuheara-35%27%
662ndSpectur-44%
730 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

18/07/19
$0 Issued
27/04/18
$19k Bought
27/04/18
$94k Sold
Total value as at the date of the transaction
Source: Morningstar

Revenue

92nd-Spectur$4.8m
93rd↑Botanix Pharmaceuticals$4.7m
95th↑Nuheara$4.5m
96th↑PharmAust$4.3m
197 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer